Nicolaus Fontanus was the first to describe amyloidosis based on the result of an autopsy while Rudolph Virchow was the first to introduce the term amyloidosis.<unk>  can be classified according to the site of amyloid deposition into glomerular, vascular, and tubular amyloidosis. Suggested mechanisms of<unk>  involvement include abnormal protein production or hereditary mutation. If left untreated,<unk>  may progress into end stage<unk>  disease. Common complications include chronic<unk>  failure and nephrotic syndrome. After a few years,<unk>  eventually leads to end stage<unk>  disease and it may be progressed  in presence of certain factors such as steroid administration,<unk>  vein thrombosis, infections and surgery. There is insufficient evidence to recommend routine screening for<unk> .<unk>  biopsy is the gold standard test for the diagnosis of<unk>  diagnosis. The mainstay of treatment for<unk>  is to decrease the production or increase clearing of amyloid. Pharmacologic medical therapies for<unk>  include colchicine, azathioprine, dimethylsulfoxide, chlorambucil, methotrexate, cyclophosphamide and TNF-alpha antagonists (ie, etanercept, infliximab, and adalimumab).
Renal amyloidosis
Phosphate nephropathy
Familial renal amyloidosis
Analgesic nephropathy
IgA nephropathy
Polycystic kidney disease
Mesoamerican nephropathy
Sucrose nephropathy